ATE551996T1 - Behandlung oder prävention von diabetes mit cannabidiol - Google Patents

Behandlung oder prävention von diabetes mit cannabidiol

Info

Publication number
ATE551996T1
ATE551996T1 AT05703237T AT05703237T ATE551996T1 AT E551996 T1 ATE551996 T1 AT E551996T1 AT 05703237 T AT05703237 T AT 05703237T AT 05703237 T AT05703237 T AT 05703237T AT E551996 T1 ATE551996 T1 AT E551996T1
Authority
AT
Austria
Prior art keywords
cannabidiol
treating
preventing diabetes
diabetes
preventing
Prior art date
Application number
AT05703237T
Other languages
English (en)
Inventor
Lola Weiss
Michael Zeira
Raphael Mechoulam
Shimon Slavin
Ruth Gallily
Original Assignee
Yissum Res Dev Co
Hadasit Med Res Service
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co, Hadasit Med Res Service filed Critical Yissum Res Dev Co
Application granted granted Critical
Publication of ATE551996T1 publication Critical patent/ATE551996T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT05703237T 2004-02-16 2005-02-16 Behandlung oder prävention von diabetes mit cannabidiol ATE551996T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL16042004A IL160420A0 (en) 2004-02-16 2004-02-16 Treating or preventing diabetes with cannabidiol
PCT/IL2005/000196 WO2005077348A1 (en) 2004-02-16 2005-02-16 Treating or preventing diabetes with cannabidiol

Publications (1)

Publication Number Publication Date
ATE551996T1 true ATE551996T1 (de) 2012-04-15

Family

ID=34073855

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05703237T ATE551996T1 (de) 2004-02-16 2005-02-16 Behandlung oder prävention von diabetes mit cannabidiol

Country Status (5)

Country Link
US (1) US8071641B2 (de)
EP (1) EP1720535B1 (de)
AT (1) ATE551996T1 (de)
IL (1) IL160420A0 (de)
WO (1) WO2005077348A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL157849A0 (en) * 2003-09-10 2004-03-28 Yissum Res Dev Co Pharmaceutical compositions containing (+) cannabidiol and derivatives thereof and some such novel derivatives
US9168278B2 (en) * 2004-11-16 2015-10-27 Gw Pharma Limited Use for cannabinoid
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
GB2450753B (en) * 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
GB2459637B (en) * 2008-01-21 2012-06-06 Gw Pharma Ltd New use for cannabinoids
WO2012000036A1 (en) * 2010-06-30 2012-01-05 Garvan Institute Of Medical Research Treatment of abnormalities of glucose metabolism with an antagonist of inhibitor of differentiation 1
GB2496687A (en) 2011-11-21 2013-05-22 Gw Pharma Ltd Tetrahydrocannabivarin (THCV) in the protection of pancreatic islet cells
US9345771B2 (en) 2012-10-04 2016-05-24 Insys Development Company, Inc. Oral cannabinoid formulations
US11253472B2 (en) 2012-10-04 2022-02-22 Benuvia Therapeutics Llc Oral cannabinoid formulations
US10265293B2 (en) 2012-10-04 2019-04-23 Insys Development Company, Inc. Oral cannabinoid formulations
US9380813B2 (en) 2014-02-11 2016-07-05 Timothy McCullough Drug delivery system and method
US9220294B2 (en) 2014-02-11 2015-12-29 Timothy McCullough Methods and devices using cannabis vapors
US10821240B2 (en) 2014-02-11 2020-11-03 Vapor Cartridge Technology Llc Methods and drug delivery devices using cannabis
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531281A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
EP3253727A4 (de) * 2015-02-05 2018-08-08 Colorado Can LLC Gereinigtes cbd und cbda sowie verfahren, zusammensetzungen und produkte mit cbd oder cbda
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
CA3077624A1 (en) 2016-10-01 2018-04-05 James Smeeding Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
CA3042493A1 (en) 2016-11-02 2018-05-11 To Pharmaceuticals Llc Combination therapy of cbd and copaxone
US20180271826A1 (en) * 2017-03-22 2018-09-27 Colorado Can Llc Dry powders of cannabinoids and methods for preparing dry powders
CN110575447B (zh) * 2018-06-07 2022-11-29 汉义生物科技（北京）有限公司 一种用于防治糖尿病的药物组合物及其用途
AU2018426503A1 (en) * 2018-06-07 2021-01-21 Hanyi Bio-Technology Company Ltd. Pharmaceutical composition for preventing diabetes and use thereof
JP2021535201A (ja) * 2018-08-20 2021-12-16 ベッソール ファルマ、エルエルシー カンナビノイドの作成のためのプロセス
CA3118317A1 (en) * 2018-10-29 2020-05-07 Keto Patent Group, Inc. Administration of butyrate, bete-hydroxybutyrate, cannabidiol, and related compounds in humans
CA3130256A1 (en) * 2019-02-15 2020-08-20 Ebers Tech Inc. L-pipecolic acid cocrystal of cannabidiol
US20220339119A1 (en) * 2019-04-03 2022-10-27 Ely Nigel Stratemeyer-Trinczek Transdermal medicament
WO2020240550A1 (en) * 2019-05-28 2020-12-03 Bol Pharma Ltd. Cannabidiol for treating type 1 diabetes mellitus
WO2021055079A1 (en) 2019-09-16 2021-03-25 Vapor Cartridge Technology Llc Drug delivery system with stackable substrates
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
KR102393416B1 (ko) * 2020-06-04 2022-05-02 재단법인 경북바이오산업연구원 대마 뿌리 추출물을 포함하는 항당뇨용 조성물
KR102393417B1 (ko) * 2020-06-04 2022-05-02 재단법인 경북바이오산업연구원 대마 줄기 추출물을 포함하는 항당뇨용 조성물
WO2022011393A1 (en) * 2020-07-08 2022-01-13 Shaman Naturals, Llc Compositions for preventing and treating diabetes
CN116983267B (zh) * 2023-09-28 2023-12-19 中国农业科学院农产品加工研究所 一种二氢大麻二酚二烟酸酯的包埋体系及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4371720A (en) * 1980-09-19 1983-02-01 Pfizer Inc. 2-Hydroxy-4-(substituted) phenyl cycloalkanes and derivatives
US5461034A (en) * 1989-02-23 1995-10-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Osteogenic growth polypeptides identified from regenerating bone marrow
US5068234A (en) 1990-02-26 1991-11-26 Sterling Drug Inc. 3-arylcarbonyl-1-(c-attached-n-heteryl)-1h-indoles
US5081122A (en) * 1990-03-05 1992-01-14 Sterling Drug Inc. Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof
US5013387A (en) * 1990-04-10 1991-05-07 Monarch Marking Systems, Inc. Hand-held labeller
IL101927A0 (en) 1992-05-19 1992-12-30 Yissum Res Dev Co Probe for cannabinoid receptors
US5618955A (en) * 1992-11-30 1997-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Fatty acid derivatives and pharmaceutical compositions containing same
IL103932A (en) 1992-11-30 1997-02-18 Yissum Res & Dev Fatty acid and pharmaceutical compositions containing them
US5292736A (en) * 1993-02-26 1994-03-08 Sterling Winthrop Inc. Morpholinoalkylindenes as antiglaucoma agents
FR2735774B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
US6017919A (en) 1996-02-06 2000-01-25 Japan Tobacco Inc. Compounds and pharmaceutical use thereof
US5948777A (en) 1997-03-18 1999-09-07 Smithkline Beecham Corporation Cannabinoid receptor agonists
KR20010021696A (ko) 1997-07-11 2001-03-15 미즈노 마사루 퀴놀린 화합물 및 그의 의약용도
IL138690A0 (en) * 1998-04-03 2001-10-31 Yissum Res Dev Co Synthetic endogenous cannabinoids, analogues and uses thereof
GB9807639D0 (en) * 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
JP2002512188A (ja) 1998-04-21 2002-04-23 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 抗酸化剤及び神経保護剤としてのカンナビノイド類
ATE277921T1 (de) * 1998-05-04 2004-10-15 Univ Connecticut Selektiv auf den cb2-rezeptor wirkende cannabinoide
US6452138B1 (en) 1998-09-25 2002-09-17 Thermosoft International Corporation Multi-conductor soft heating element
TWI234557B (en) * 1999-05-26 2005-06-21 Telik Inc Novel naphthalene ureas as glucose uptake enhancers
CA2386985A1 (en) * 2000-08-11 2002-02-21 The Lawson Health Research Institute Compositions and methods for inhibiting islet dysfunction and autoimmune disorders
US6403123B1 (en) * 2000-09-19 2002-06-11 Eugene J. Van Scott Method for topical treatment of anthralin-responsive dermatological disorders
WO2003063847A1 (en) 2002-02-01 2003-08-07 Gw Pharma Limited Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions

Also Published As

Publication number Publication date
US8071641B2 (en) 2011-12-06
EP1720535B1 (de) 2012-04-04
WO2005077348A1 (en) 2005-08-25
EP1720535A1 (de) 2006-11-15
US20070099987A1 (en) 2007-05-03
IL160420A0 (en) 2004-07-25

Similar Documents

Publication Publication Date Title
ATE551996T1 (de) Behandlung oder prävention von diabetes mit cannabidiol
EA200601746A1 (ru) Применение ротиготина для лечения и предупреждения синдрома "паркинсонизм-плюс"
MY170728A (en) Treatment for diabetes in patients inappropriate for metformin therapy
DE60336754D1 (de) Enzymbehandlung von nahrungsmitteln für zöliakie-sprue
DE602005019856D1 (de) Mittel zur behandlung von hyperlipidämie mit pitavastatinen und eicosapentaensäure
HK1121074A1 (en) Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione
EA200801717A1 (ru) Композиция местного применения по уходу за кожей, продукт на ее основе и способ лечения
MY174080A (en) Use of dpp iv inhibitors
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
BR0313282A (pt) Composições de inibidor seletivo de ciclooxigenase-2 e um inibidor de anidrase carbÈnica para o tratamento de neoplasia
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
EA200701845A1 (ru) Рофлумиласт для лечения сахарного диабета
DE60204966D1 (de) Verwendung von cyclopamine zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis
ATE475414T1 (de) Tuberkulosebehandlung mit pleuromutilinderivaten
MXPA06012143A (es) Arilsulfonamidas y usos relacionados con las mismas.
ATE393625T1 (de) Behandlung und prävention von übermässiger narbenbildung mit 4-hydroxy tamoxifen
MXPA05001885A (es) El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica.
EA200702189A1 (ru) Способ лечения и профилактики диабета второго типа
TW200503676A (en) Use of kynurenine 3-hydroxylase inhibitors for the treatment of diabetes
DE602006020838D1 (de) Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DK1675611T3 (da) Terapeutiske anvendelser for C-peptid
DE50202331D1 (de) Verwendung eines phosphatadsorbers gegen gefässerkrankungen
EA200801023A1 (ru) Применение фенофибрата или его производного для предотвращения диабетической ретинопатии
ATE503489T1 (de) Behandlung von akutem nierenversagen mit löslichem thrombomodulin